专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO9929705A9 SIALYL LEWIS X AND SIALYL LEWIS A GLYCOMIMETICS 审中-公开
标题翻译： SIALYL LEWIS X和SIALYL LEWIS GLYCOMIMETICS
公开(公告)号：WO9929705A9
公开(公告)日：1999-11-11
申请号：PCT/US9825783
申请日：1998-12-04
申请人： GLYCOMED INC , SANKYO CO , ANDERSON MARK B , KOBAYASHI YOSHIYUKI , ITOH KAZUHIRO , HOLME KEVIN R , CUI JINGRONG , FUGEDI PETER , PETO CSABA F , WANG LI , VAZIR HARISH
发明人： ANDERSON MARK B , KOBAYASHI YOSHIYUKI , ITOH KAZUHIRO , HOLME KEVIN R , CUI JINGRONG , FUGEDI PETER , PETO CSABA F , WANG LI , VAZIR HARISH
IPC分类号： C07H13/00 , C07H13/04 , C07H13/08 , C07H13/10 , C07H13/12 , C07H15/26 , C07D309/10 , A61K31/35 , A61K31/70 , C07C229/46 , C07D211/60 , C07D309/06
CPC分类号： C07H13/04 , C07H13/00 , C07H13/08 , C07H13/10 , C07H13/12 , C07H15/26
摘要： The present invention provides a series of compounds in the form of chemically and physiologically stable glycomimics or glycoepitopes that serve to functionally mimic the active features of biologically important oligosaccharides, such as but not limited to sialyl Lewis (sLe ) and sialyl Lewis (sLe ). These structural Glycomimetics have been shown to be useful in the treatment of acute and chronic diseases as well as for the treatment of asthma. These compounds also are useful in the treatment of other selectin-mediated disorders, such as inflammation, cancer, diabetes, obesity, lung vasculitis, cardiac injury, reperfusion injuries, thrombosis, tissue rejection, arthritis, inflammatory bowel disease and pulmonary inflammation.
摘要翻译：本发明提供了一系列化学和生理学稳定的糖缀合物或糖表位形式的化合物，其用于功能性模拟生物学重要的寡糖的活性特征，例如但不限于唾液酸Lewis x（sLe x）和唾液酸Lewis aa（sLe a）。已经显示这些结构糖模拟物可用于治疗急性和慢性疾病以及治疗哮喘。这些化合物还可用于治疗其他选择素介导的病症，例如炎症，癌症，糖尿病，肥胖症，肺血管炎，心脏损伤，再灌注损伤，血栓形成，组织排斥，关节炎，炎症性肠病和肺部炎症。

12. 发明申请

WO2012151503A2 MULTIPLEXED GENETIC REPORTER ASSAYS AND COMPOSITIONS 审中-公开
标题翻译：多功能遗传记录仪测定及组合物
公开(公告)号：WO2012151503A2
公开(公告)日：2012-11-08
申请号：PCT/US2012036558
申请日：2012-05-04
申请人： BROAD INST INC , MIKKELSEN TARJEI , GNIRKE ANDREAS , MELNIKOV ALEXANDRE , LANDER ERIC S , WANG LI , ZHANG XIAOLAN
发明人： MIKKELSEN TARJEI , GNIRKE ANDREAS , MELNIKOV ALEXANDRE , LANDER ERIC S , WANG LI , ZHANG XIAOLAN
IPC分类号： C12N15/63 , C12N15/11
CPC分类号： C12Q1/6897 , C12N15/1086 , C12N15/63
摘要： The invention provides methods for determining the activity of a plurality of nucleic acid regulatory elements. These methods may facilitate, e.g., the systematic reverse engineering, and optimization of mammalian cis-regulatory elements at high resolution and at a large scale. The method may include integration of multiplexed DNA synthesis and sequencing technologies to generate and quantify the transcriptional regulatory activity of, e.g., thousands of arbitrary DNA sequences in parallel in cell-based assays (e.g., mammalian cell based assays).
摘要翻译：本发明提供了确定多种核酸调节元件的活性的方法。这些方法可以促进例如系统逆向工程，并且以高分辨率和大规模优化哺乳动物顺式调节元件。该方法可以包括多元化DNA合成和测序技术的整合，以在基于细胞的测定（例如，基于哺乳动物细胞的测定）中平行产生和定量数千个任意DNA序列的转录调节活性。

13. 发明申请

WO2011011631A3 NUCLEIC ACID DELIVERY VEHICLES 审中-公开
标题翻译：核酸递送车辆
公开(公告)号：WO2011011631A3
公开(公告)日：2011-03-17
申请号：PCT/US2010042951
申请日：2010-07-22
申请人： ZALIPSKY SAMUEL , WANG LI , DING ZHONGLI , LUO BING
发明人： ZALIPSKY SAMUEL , WANG LI , DING ZHONGLI , LUO BING
IPC分类号： A61K48/00 , A61K9/14
CPC分类号： C12N15/87
摘要： The invention provides a stable nanoparticle for nucleic acid delivery to cells and tissues in vitro and in vivo, methods for making and using the nanoparticle for at least therapeutic and diagnostic purposes.
摘要翻译：本发明提供了用于在体外和体内向细胞和组织递送核酸的稳定的纳米颗粒，用于制备和使用纳米颗粒至少具有治疗和诊断目的的方法。

14. 发明申请

WO2008011289A3 HYDROCRACKING CATALYST CONTAINING BETA AND Y ZEOLITES, AND PROCESS FOR ITS USE TO MAKE DISTILLATE 审中-公开
标题翻译：含β和Y沸石的加氢裂化催化剂及其用于制备馏出物的方法
公开(公告)号：WO2008011289A3
公开(公告)日：2008-03-20
申请号：PCT/US2007073043
申请日：2007-07-09
申请人： UOP LLC , WANG LI
发明人： WANG LI
IPC分类号： C10G11/02 , B01J29/00
CPC分类号： C10G47/16 , B01J23/28 , B01J23/30 , B01J23/75 , B01J23/755 , B01J23/85 , B01J29/084 , B01J29/7007 , B01J29/80 , B01J37/0201 , C10G47/20
摘要： Increased selectivity of middle distillate and/or increased catalyst activity are obtained in a hydrocracking process by the use of a catalyst containing a beta zeolite and a Y zeolite having a unit cell size of 24.33 to 24.38 angstrom. The catalyst may also contain an additional Y zeolite having a unit cell size of from 24.25 to 24.32 angstrom.
摘要翻译：通过使用含有β沸石和晶胞尺寸为24.33至24.38埃的Y型沸石的催化剂，在加氢裂化过程中获得中间馏分的选择性增加和/或催化剂活性增加。催化剂还可以含有另外的晶胞尺寸为24.25-24.32埃的Y型沸石。

15. 发明申请

WO2011072246A3 TAL EFFECTOR-MEDIATED DNA MODIFICATION 审中-公开
公开(公告)号：WO2011072246A3
公开(公告)日：2012-02-02
申请号：PCT/US2010059932
申请日：2010-12-10
申请人： UNIV MINNESOTA , UNIV IOWA STATE RES FOUND INC , VOYTAS DANIEL F , BOGDANOVE ADAM , ZHANG FENG , CHRISTIAN MICHELLE , CERMAK TOMAS , SCHMIDT CLARICE LAUER , DOYLE ERIN , WANG LI
发明人： VOYTAS DANIEL F , BOGDANOVE ADAM , ZHANG FENG , CHRISTIAN MICHELLE , CERMAK TOMAS , SCHMIDT CLARICE LAUER , DOYLE ERIN , WANG LI
IPC分类号： C12N15/10 , C12N15/82
CPC分类号： C12N9/22 , C12N15/01 , C12N15/102 , C12N15/1082 , C12N15/62 , C12N15/63 , C12Y301/21004
摘要： Materials and methods related to gene targeting (e.g., gene targeting with transcription activator-like effector nucleases; "TALENS") are provided.
摘要翻译：提供了与基因靶向相关的材料和方法（例如，用转录激活子样效应核酸酶进行基因靶向;“TALENS”）。

16. 发明申请

WO2007126419A2 HYDROCRACKING CATALYST CONTAINING BETA AND Y ZEOLITES, AND PROCESS FOR ITS USE TO MAKE JET FUEL OR DISTILLATE 审中-公开
标题翻译：含有BETA和Y沸石的水解催化剂及其用于喷射燃料或蒸馏的方法
公开(公告)号：WO2007126419A2
公开(公告)日：2007-11-08
申请号：PCT/US2006042775
申请日：2006-11-02
申请人： UOP LLC , WANG LI
发明人： WANG LI
IPC分类号： C10G11/00 , B01J29/08
CPC分类号： C10G47/16 , B01J23/882 , B01J23/883 , B01J23/888 , B01J29/084 , B01J29/7007 , B01J29/80 , B01J37/0201 , B01J37/26 , B01J2229/32 , C10G47/20 , C10G2300/301 , C10G2300/4006 , C10G2300/4012 , C10G2400/08
摘要： Increased yields of middle distillate and jet fuel and increased catalyst activity are obtained in a hydrocracking process by the use of a catalyst containing a beta zeolite and a Y zeolite having a unit cell size from 24.37 to 24.44 angstrom. The catalyst has a relatively high amount of Y zeolite relative to beta zeolite.
摘要翻译：通过使用含有β沸石的催化剂和具有24.37至24.44埃的晶胞尺寸的Y沸石，在加氢裂化过程中获得了中间馏分和喷气燃料的产率提高和催化剂活性的增加。催化剂相对于β沸石具有相对高量的Y沸石。

17. 发明申请

WO2007079343A3 CLOSED LOOP OPTIMIZATION OF A-V AND V-V TIMING 审中-公开
标题翻译： A-V和V-V时序的闭环优化
公开(公告)号：WO2007079343A3
公开(公告)日：2007-09-27
申请号：PCT/US2006062098
申请日：2006-12-14
申请人： MEDTRONIC INC , WANG LI
发明人： WANG LI
IPC分类号： A61N1/365 , A61N1/368
CPC分类号： A61N1/3756 , A61B5/0452 , A61B5/0472 , A61N1/362 , A61N1/3627 , A61N1/365 , A61N1/3682 , A61N1/3684
摘要： Embodiments of close loop optimization of atrioventricular (A-V) delay interval and/or inter-ventricular (V-V) timing are disclosed. An implantable medical device includes a . housing that supports a processing means adapted for implantation in a patient, There can be two or more electrodes electrically coupled to the processing means where the two or more electrodes can be used for sensing a patient's cardiac signals, which include a far-field EGM. The processing means can determine a width of a P-wave from the sensed far-field EGM Also included can be a means for delivering an adapted cardiac pacing therapy based upon the width of the P-wave, including revised A-V delay and/or V-V temporal intervals.
摘要翻译：公开了房室（A-V）延迟间隔和/或心室间（V-V）定时的闭环优化的实施例。一种可植入医疗器械包括：a。支撑适于植入患者体内的处理装置的外壳。可以有两个或更多电极与处理装置电耦合，其中两个或更多个电极可用于感测患者的心脏信号，其包括远场EGM。处理装置可以根据感测的远场EGM确定P波的宽度。还可以包括用于基于P波的宽度传送适应的心脏起搏治疗的装置，包括修正的AV延迟和/或VV 时间间隔。

18. 发明申请

WO2006081230A3 3-(INDAZOL-5-YL)-(1,2, 4) TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER 审中-公开
标题翻译： 3-（INDAZOL-5-YL） - （1,2,4）TRIAZINE衍生物及相关化合物作为蛋白激酶抑制剂治疗癌症
公开(公告)号：WO2006081230A3
公开(公告)日：2006-10-19
申请号：PCT/US2006002437
申请日：2006-01-24
申请人： SCHERING CORP , CHAN TIN-YAU , FISCHMANN THIERRY O , MC COY MARK A , MC KITTRICK BRIAN , PRONGAY ANDREW , PU HAIYAN , WANG LI , XIAO LI
发明人： CHAN TIN-YAU , FISCHMANN THIERRY O , MC COY MARK A , MC KITTRICK BRIAN , PRONGAY ANDREW , PU HAIYAN , WANG LI , XIAO LI
IPC分类号： C07D403/04 , A61P35/00
CPC分类号： C07D403/04
摘要： The present invention relates to indazolyl (1;2,4) triazine compounds having the general structure of Formula (I); useful as protein kinase inhibitors, pharmaceutical compositions comprising such compounds, and methods of treatment using the compounds and compositions to treat conditions such as cancer and proliferative diseases or immunodeficiencies, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease. The substituents are defined in the claims.
摘要翻译：本发明涉及具有通式（I）的通式结构的吲唑基（1; 2,4）三嗪化合物。可用作蛋白激酶抑制剂，包含这些化合物的药物组合物和使用化合物和组合物治疗诸如癌症和增殖性疾病或免疫缺陷症的心血管疾病，内分泌障碍，帕金森病，代谢疾病，肿瘤发生，阿尔茨海默病，心脏病，糖尿病，神经变性，炎症，肾脏疾病，动脉粥样硬化和气道疾病。取代基在权利要求中限定。

19. 发明申请

WO2005037367A3 METHOD AND APPARATUS FOR MONITORING TISSUE FLUID CONTENT FOR USE IN AN IMPLANTABLE CARDIAC DEVICE 审中-公开
标题翻译：用于监测组织液含量的方法和装置，用于可植入心脏装置
公开(公告)号：WO2005037367A3
公开(公告)日：2005-06-09
申请号：PCT/US2004034078
申请日：2004-10-14
申请人： MEDTRONIC INC , WANG LI , CHO YONG KYUN , KUEHN KEVIN , ZILLMER GLENN C
发明人： WANG LI , CHO YONG KYUN , KUEHN KEVIN , ZILLMER GLENN C
IPC分类号： A61B5/053 , A61N1/362 , A61N1/365 , A61N1/39
CPC分类号： A61B5/4869 , A61B5/0537 , A61B5/0538 , A61B5/7203 , A61B5/7285 , A61N1/3627 , A61N1/36521 , A61N1/3962
摘要： A fluid status monitoring system for use in implantable cardiac stimulation or monitoring devices is provided for monitoring changes in thoracic fluid content. A fluid status monitor includes excitation pulse generating and control circuitry, and voltage and current measurement and control circuitry for performing a series of cardiac-gated, intra-thoracic impedance measurements. The cardiac-gated measurements are filtered or time-averaged to provide a fluid status impedance value, with respiratory noise removed. Based on comparative analysis of the fluid status impedance value, a clinically relevant trend in fluid status may be tentatively diagnosed and a fluid status response provided. Cross-check intra-thoracic impedance measurements performed using the same or a different excitation pathway and a different measurement pathway than the primary intra-thoracic impedance measurement configuration may be used to verify a tentative diagnosis.
摘要翻译：提供用于植入式心脏刺激或监测装置的流体状态监测系统，用于监测胸腔液含量的变化。流体状态监测器包括激励脉冲发生和控制电路以及用于执行一系列心脏门控胸腔内阻抗测量的电压和电流测量和控制电路。心脏门控测量被过滤或时间平均以提供流体状态阻抗值，消除呼吸噪声。基于流体状态阻抗值的比较分析，可以暂时诊断流体状态的临床相关趋势，并提供流体状态响应。使用与主要的胸内阻抗测量配置相同或不同的激发途径和不同的测量途径进行的交叉检查胸内阻抗测量可用于验证临时诊断。

20. 发明申请

WO2004096041A3 METHOD AND APPARATUS FOR IMPEDANCE SIGNAL LOCALIZATIONS FROM IMPLANTED DEVICES 审中-公开
标题翻译：用于阻挡信号局部化的方法和装置
公开(公告)号：WO2004096041A3
公开(公告)日：2004-12-02
申请号：PCT/US2004011470
申请日：2004-04-14
申请人： MEDTRONIC INC , WANG LI
发明人： WANG LI
IPC分类号： A61B5/053 , A61B5/08 , A61N1/365 , A61N1/37
CPC分类号： A61N1/36521 , A61B5/053 , A61B5/0809 , A61B5/7285
摘要： Method and apparatus for monitoring a plurality of physiological factors contributing to physiological conditions of a heart, that determines a first impedance, corresponding to the plurality of physiological factors, across a plurality of vectors, and a second impedance, corresponding to the plurality of physiological factors, across the plurality of vectors subsequent to determining the first impedance. A relative change in impedance corresponding to the plurality of vectors is determined in response to the first impedance and the second impedance, first minimally contributing physiological factors of the plurality of physiological factors associated with a first physiological factor of the plurality of physiological factors are determined, and relative change in tissue resistivity corresponding to the first physiological factor in response to physiological factors of the plurality of physiological factors other than the first minimal contributing physiological factors and the relative change in impedance are determined.
摘要翻译：用于监测有助于心脏生理状态的多个生理因子的方法和装置，其确定对应于多个向量的多个生理因素的第一阻抗和对应于多个生理因子的第二阻抗在确定第一阻抗之后跨越多个向量。响应于第一阻抗和第二阻抗确定与多个向量相对应的阻抗的相对变化，确定与多个生理因子中的第一生理因子相关联的多个生理因子的第一最小贡献的生理因子，并且确定响应于除了第一最小贡献生理因子之外的多个生理因素的生理因素和阻抗的相对变化的对应于第一生理因子的组织电阻率的相对变化。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式